Hims & Hers Health, Inc. HIMS
19.13 USD -3.81 (-16.61%)
At closeNov 10, 2026, 4:30 PM EST
18.88 -0.25 -1.31%
After hours · Nov 10, 4:30 PM ET
18.40 Day range 22.47
13.74 52-week range 41.28
- YTD
- -41.08%
- 1 year
- -53.40%
News
benzinga.com Weight-Loss Reset Dents Hims & Hers Outlook, But Analyst Sees Opportunity Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results and trimmed guidance on Monday.
benzinga.com Weight-Loss Reset Dents Hims & Hers Outlook, But Analyst Sees Opportunity Hims & Hers stock dropped after a Q3 loss and guidance cut, but Needham reaffirmed its Buy rating, seeing the post-earnings pullback as an entry point.
247wallst.com Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.
247wallst.com Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week.
benzinga.com Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Lowers Price Target to $25 Morgan Stanley analyst Craig Hettenbach maintains Hims & Hers Health (NYSE:HIMS) with a Equal-Weight and lowers the price target from $28 to $25.
youtube.com HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus Marley Kayden crunches the numbers on Hims & Hers (HIMS) earnings and its worse-than-expected revenue growth. The stock plunged following the opening bell as investors question the telehealth…
benzinga.com These Analysts Revise Their Forecasts On Hims & Hers Health After Q3 Results Hims & Hers missed Q3 FY26 earnings and revenue estimates, cut guidance, and shares fell 13%; analysts revised price targets.
seekingalpha.com Hims & Hers: Why I'm Not Buying Back Yet (Rating Downgrade) Hims & Hers grew Q3 revenue 49% to $890.4 million, but adjusted EBITDA increased just $4 million to $82.4 million. Gross margin contracted from 73.8% to 57.2%, while subscribers declined 100,000…
benzinga.com Evercore ISI Group Maintains In-Line on Hims & Hers Health, Raises Price Target to $27 Evercore ISI Group analyst Mark Mahaney maintains Hims & Hers Health (NYSE:HIMS) with a In-Line and raises the price target from $24 to $27.
benzinga.com Hims & Hers Stock Feels a Pinch Tuesday: What's Happening? Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after the company reported worse-than-expected third-quarter financial results Monday after the market closed. Also, Needham…- benzinga.com Hims & Hers Stock Feels a Pinch Tuesday: What's Happening? Hims & Hers Health Inc. (NYSE: HIMS) shares are trading lower Tuesday after the company reported worse-than-expected Q3 results late Monday.
247wallst.com Hims & Hers Just Warned Investors for the Third Time This Year. CEO Andrew Dudum Calls the Subscriber Losses a Trade He'll Make ‘Every Time' Hims & Hers cut its 2026 adjusted EBITDA outlook for the third time this year, to $257 million to $277 million from February's $300 million to $375 million, posted a surprise $33 million loss, and…
fool.com Hims & Hers: 3 Key Takeaways for Long-Term Investors Revenue grew 49% year-over-year to $890 million in the third quarter. Subscribers reached 2.8 million despite a 100,000 net subscriber decline.
benzinga.com Needham Maintains Buy on Hims & Hers Health, Lowers Price Target to $32 Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and lowers the price target from $42 to $32.
marketbeat.com What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call Hims & Hers Health NYSE: HIMS reported third-quarter revenue growth of 49% but lost 100,000 subscribers from the prior quarter, as the digital health company held back U.S. weight-loss marketing and…
seekingalpha.com Hims & Hers Health, Inc. (HIMS) Q3 2026 Earnings Call Transcript Hims & Hers Health, Inc. ( HIMS ) Q3 2026 Earnings Call November 9, 2026 5:00 PM EST Company Participants William Newby - Senior Director of Investor Relations Andrew Dudum - Co-Founder, Chairman &…
benzinga.com Hims & Hers Health Q3 2026 Earnings Call Transcript Hims & Hers Health (NYSE:HIMS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Hims & Hers Stock Slips Further as Q3 Print Disappoints Here's a detailed look inside the Q3 earnings report from Hims & Hers Health.- benzinga.com Hims & Hers Health Q3 EPS $(0.14) Misses $0.08 Estimate, Sales $890.373M Miss $892.888M Estimate Hims & Hers Health (NYSE:HIMS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $0.08 by 275 percent. This is a 255.56 percent decrease over earnings of…
- benzinga.com Hims & Hers Health Narrows FY2026 Sales Guidance from $3.100B-$3.300B to $3.130B-$3.150B vs $3.209B Est Hims & Hers Health (NYSE:HIMS) narrows FY2026 sales outlook from $3.100 billion-$3.300 billion to $3.130 billion-$3.150 billion vs $3.209 billion estimate.
benzinga.com Hims & Hers Health Sees Q4 Sales $875.000M-$895.000M vs $953.446M Est Hims & Hers Health (NYSE:HIMS) sees Q4 sales of $875.000 million-$895.000 million vs $953.446 million analyst estimate.
benzinga.com Hims & Hers Stock Plunges Before Earnings: What to Watch Hims & Hers Health shares are plummeting Monday ahead of its Q3 earnings report, which is scheduled for release after the market close.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Hims & Hers Short Interest Climbs to 23% Ahead of Earnings: Can the Stock Break Out? Hims & Hers Health stock has lost momentum this year. After peaking at $72.78 in 2025, it has slumped about 65% to the current $26.
fool.com Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027? Hims & Hers Health is leveraging a high-growth, subscription-based digital platform to provide personalized treatments for weight loss and sexual health. Intuitive Surgical maintains a dominant…
benzinga.com Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
investors.com Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs, further entrenching itself in the GLP-1 space.
barrons.com Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.
benzinga.com Eli Lilly And Hims & Hers Partner To Expand Access To Zepbound And Orforglipron At Standard Self-Pay Prices Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformEli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced…
seekingalpha.com 3 High Conviction Stocks + Charitable Giving: Tax Alpha With Raul Shah Raul Shah explains how value investing can help investors navigate volatile markets, highlighting opportunities in Hims & Hers (HIMS), ServiceNow (NOW), and UnitedHealth (UNH). HIMS demonstrates…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit Hims & Hers seeks dismissal of a consumer lawsuit, arguing upfront disclosures refute claims about user privacy, billing, and cancellations.
benzinga.com 4 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com 8 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.
benzinga.com How Did BONER Meme Coin Create One of Robinhood's Biggest Stories? BONER locks up half of tokenized Hims & Hers supply on Robinhood Chain, briefly sending HIMS tokens to $132 before arbitrage restores prices.- benzinga.com Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study…
- benzinga.com Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $32 Truist Securities analyst Jailendra Singh maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $27 to $32.
- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35 Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.
benzinga.com Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access Hims & Hers CEO Andrew Dudum defends the firm against an FTC lawsuit, discusses dropping GLP-1 drug prices and reveals in-house AI plans.- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33 Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and lowers the price target from $35 to $33.- benzinga.com Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26 Deutsche Bank analyst George Hill maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $25 to $26.